Current Yachts announced its official launch with a mission to transform the yacht brokerage industry by eliminating excessive commissions and putting consumers first. The company's innovative model is a service-based, patent-pending approach, where traditional 8-10% commission structures are replaced with transparent, flat-rate pricing while maintaining the highest professional standards.
Read MoreConsero Global Fortifies Executive Leadership with Key Technology and Corporate Development Appointments to Accelerate Growth and Innovation
Read MoreNew Capabilities Place Peer-reviewed Literature Review Evidence at the Fingertips of Research and Commercial Teams to Align Decision-making and Improve Productivity
Read More
Keensight Capital ("Keensight"), one of the leading private equity managers dedicated to pan-European Growth Buyout [1] investments, today announced it has agreed to acquire a majority stake in Isto Biologics ("Isto") from Thompson Street Capital Partners ("TSCP"). TSCP will retain a minority stake, alongside Isto Biologics' management team.
BUZZ BOMB™ engages three specialized fitness influencers to grow the brand
The influencers have hundreds of thousands of followers across social platforms
BUZZ BOMB's™ influencers known for their authenticity and ability to create genuine connections with their followers in the fitness and health world
Sublingual delivery of 50mg of caffeine to the user in less than two minutes
BUZZ BOMB™ is available for purchase at buzzbomb.buzz, the Company's E-commerce website
Already generating millions in revenue, Irregular partners with leading labs like OpenAI and Anthropic to assess advanced models under real-world threats and define the security frameworks for safe deployment
Read MoreIcotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies
Icotrokinra also showed sustained skin clearance and favorable safety profile in both adults and adolescents at Week 52 in Phase 3 ICONIC-LEAD study
Preclinical proof-of-concept data on PN-881, a first-in-class oral peptide targeting the IL-17 pathway, and part of Protagonist's fully owned development pipeline, including the highly potent and selective binding of IL-17A and IL-17F
Read More
